KUALA LUMPUR (Nov 10): Hartalega Holdings Bhd will launch the world’s first non-leaching antimicrobial nitrile examination glove into the market early next year to help reduce hospital-acquired infection.
“Traditionally, medical examination gloves are a passive barrier to reduce the risks of transmission of infection in healthcare settings. With this state-of-the art technology, we are able to develop gloves that provide active protection...we have successfully conducted production trials and further clinical studies are planned to quantitate the benefits of using antimicrobial medical examination gloves in clinical settings. We are scheduled to launch in the market in early 2018,” the Group’s managing director, Kuan Mun Leong, said in a statement today.
Kuan said the non-leaching antimicrobial nitrile examination gloves will be attractive to hospitals and other users such as residential care homes because of their potential to reduce hospital-acquired infections arising from contamination of the gloved hands of healthcare workers, patients and near-patient touch surfaces.
He said that hospital-acquired infections are frequently transmitted to patients by the hands of healthcare practitioners, as contamination can occur when taking a patient’s pulse, blood pressure, or temperature, or from contact with surfaces near patients.
Kuan said research has found that on an annual basis, hospital-acquired infections affect approximately 2 million hospital patients in the United States, resulting in 90,000 deaths and additional costs of US$28 to US$45 billion.
"In the European Union, hospital-acquired infections affect 4.1 million patients per year, resulting in 37,000 deaths and additional costs of 7 billion euros, as reported by the European Centre for Disease Prevention and Control,” he said, adding that most of these infections are resistant to multiple antibiotics, which makes them difficult to treat.
The world’s largest manufacturer of premium quality nitrile gloves, shared that the Group has jointly developed the patented technology with United Kingdom-based Antimicrobial R&D specialist Chemical Intelligence Limited, to incorporate antimicrobial activity in medical examination gloves during the manufacturing process.
At the noon break, Hartalega’s share price gained by 3.01% to RM8.55 with about 2.1 million shares traded, giving it a market capitalisation of RM14.1 billion.
http://www.theedgemarkets.com/article/hartalega-launch-worlds-first-innovation-glove-technology
“Traditionally, medical examination gloves are a passive barrier to reduce the risks of transmission of infection in healthcare settings. With this state-of-the art technology, we are able to develop gloves that provide active protection...we have successfully conducted production trials and further clinical studies are planned to quantitate the benefits of using antimicrobial medical examination gloves in clinical settings. We are scheduled to launch in the market in early 2018,” the Group’s managing director, Kuan Mun Leong, said in a statement today.
Kuan said the non-leaching antimicrobial nitrile examination gloves will be attractive to hospitals and other users such as residential care homes because of their potential to reduce hospital-acquired infections arising from contamination of the gloved hands of healthcare workers, patients and near-patient touch surfaces.
 |
| HARTA (5168) - Hartalega to launch world's first innovation in glove technology |
He said that hospital-acquired infections are frequently transmitted to patients by the hands of healthcare practitioners, as contamination can occur when taking a patient’s pulse, blood pressure, or temperature, or from contact with surfaces near patients.
Kuan said research has found that on an annual basis, hospital-acquired infections affect approximately 2 million hospital patients in the United States, resulting in 90,000 deaths and additional costs of US$28 to US$45 billion.
"In the European Union, hospital-acquired infections affect 4.1 million patients per year, resulting in 37,000 deaths and additional costs of 7 billion euros, as reported by the European Centre for Disease Prevention and Control,” he said, adding that most of these infections are resistant to multiple antibiotics, which makes them difficult to treat.
The world’s largest manufacturer of premium quality nitrile gloves, shared that the Group has jointly developed the patented technology with United Kingdom-based Antimicrobial R&D specialist Chemical Intelligence Limited, to incorporate antimicrobial activity in medical examination gloves during the manufacturing process.
At the noon break, Hartalega’s share price gained by 3.01% to RM8.55 with about 2.1 million shares traded, giving it a market capitalisation of RM14.1 billion.
http://www.theedgemarkets.com/article/hartalega-launch-worlds-first-innovation-glove-technology
